• Volition Launches NuQ® Epigenetic Immunoassays for Research Use

  • VolitionRX to Begin Prospective Clinical Trial in Colon Cancer

  • VolitionRX Issues CEO Letter to Shareholders

  • VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany

  • VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests

  • Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer

  • Volition Signs Collaboration Agreement With Abcodia